Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprubart and Everolimus for Pancreatic Islet Transplantation in T1DM and CKD
NCT07592000Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Apr 2027
- Primary completion
- Jan 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegoprubart in type 1 diabetes mellitus (T1D) and chronic kidney disease (CKD), sponsored by University of Chicago. Primary endpoints: Optimal outcomes according to Igls criteria at 1 year and Good outcomes according to Igls criteria at 1 year. Planned start Apr 2027; status: recruiting.
02
Drugs
tegoprubart
03
Conditions
type 1 diabetes mellitus (T1D)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07592000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07592000.